Jun 2026 (Q2 FY26) — Jul 29, 2026
Adaptive Biotechnologies Q2 FY26 — Strong MRD Growth and Immune Medicine Separation Plan
Read the full callAdaptive Biotechnologies (ADPT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Adaptive Biotechnologies earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 71.6 | +21.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -22.0 | +20.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -39.8 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$23.95 −0.29% · −$0.07
Performance +46.9% 1Y
1Y: $16.3 on 17 Oct 2025 → $23.95. High $29.84 (5 Oct 2026), low $12.41 (27 Mar 2026).
- Previous close
- $24.02
- 52-week range
- $12.41 – $29.84
- One year
- +34.32%
Overview
- Symbol
- ADPT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Adaptive Biotechnologies earnings calls (ADPT)
Financials
What the filings say
Net profit, year on year: −55% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 47 | 52 | 59 | 94 | 72 | 71 | 72 |
| Expenses | 79 | 81 | 82 | 84 | 84 | 84 | 90 | 87 |
| Operating profit | -33 | -34 | -30 | -25 | 10 | -13 | -19 | -16 |
| Operating margin | −70.3% | −71.3% | −56.5% | −42.5% | 10.9% | −17.8% | −27.1% | −22.0% |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Net profit | -32 | -34 | -30 | -26 | 10 | -14 | -20 | -40 |
| EPS ($ per share) | -0.22 | — | -0.20 | -0.17 | 0.06 | — | -0.13 | -0.25 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -296 | -365 | -512 | -719 | -919 | -1,144 | -1,304 | -1,363 |
| Total liabilities | 30 | 341 | 373 | 319 | 393 | 353 | 337 | 288 |
| Fixed assets | 19 | 60 | 40 | 85 | 83 | 68 | 49 | 34 |
| Total assets | 333 | 912 | 1,116 | 923 | 857 | 661 | 539 | 513 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -32 | 205 | -150 | -193 | -184 | -156 | -95 | -46 |
| Cash from investing | 1 | -482 | -117 | 181 | 3 | 130 | 78 | 38 |
| Cash from financing | 1 | 320 | 294 | 27 | 132 | 2 | 0 | 30 |
| Net cash flow | -30 | 44 | 27 | 16 | -49 | -24 | -17 | 22 |
| Capital expenditure | -6 | -11 | -19 | -62 | -16 | -11 | -4 | -3 |
| Free cash flow | -39 | 194 | -168 | -254 | -200 | -167 | -99 | -49 |
ADPT revenue by segment
Mrd Business grew from 81% to 92% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Mrd Business | 81% | 85% | 83% | 85% | 60% | 86% | 95% | 92% | +32.5% |
| Immune Medicine Business | 19% | 15% | 17% | 15% | 40% | 14% | 5% | 8% | -39.8% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
289 filings between Nov 10, 2025 and Oct 16, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$126.67M
151 sales by 11 insiders
85% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 123
- Option exercise — converted options into shares
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| ROBINS CHAD M | — | $39.80M | Aug 18, 2026 |
| ROBINS HARLAN S | — | $29.65M | Jul 21, 2026 |
| RUBINSTEIN JULIE | — | $17.15M | Oct 16, 2026 |
| BENZENO SHARON | — | $14.69M | Jun 29, 2026 |
| LO FRANCIS | — | $13.89M | Oct 1, 2026 |
| PISKEL KYLE | — | $3.58M | May 18, 2026 |
| NEUPERT PETER M | — | $3.14M | Aug 17, 2026 |
| GRIFFIN MICHELLE RENEE | — | $2.00M | Jun 25, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 16, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 11,581 | $280.4K |
| Oct 16, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 16, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 300 | $7.6K |
| Oct 15, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 11,881 | $304.3K |
| Oct 15, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 14, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 6,781 | $173.4K |
| Oct 14, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 14, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 5,100 | $131.7K |
| Oct 13, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 11,881 | $303.0K |
| Oct 13, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 12, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 9,181 | $232.7K |
| Oct 12, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 12, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 2,700 | $70.4K |
| Oct 9, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 9, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 11,881 | $313.8K |
| Oct 8, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 8, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 11,881 | $304.9K |
| Oct 7, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 11,881 | $313.7K |
| Oct 7, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 6, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 1,100 | $31.0K |
| Oct 6, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 901 | $26.8K |
| Oct 6, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 499 | $15.2K |
| Oct 6, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 9,381 | $256.7K |
| Oct 6, 2026 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Sale 10b5-1 plan | 6,444 | $193.3K |
| Oct 6, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 5, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 5, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 6,699 | $193.1K |
| Oct 5, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 5,182 | $153.7K |
| Oct 2, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 2, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 11,881 | $334.2K |
| Oct 1, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 5,800 | $165.6K |
| Oct 1, 2026 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 plan | 8,038 | $68.0K |
| Oct 1, 2026 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 plan | 9,377 | $37.4K |
| Oct 1, 2026 | LO FRANCIS Chief People Officer | Sale 10b5-1 plan | 8,094 | $222.7K |
| Oct 1, 2026 | LO FRANCIS Chief People Officer | Sale 10b5-1 plan | 18,698 | $534.9K |
| Oct 1, 2026 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 plan | 11,881 | $144.2K |
| Oct 1, 2026 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 plan | 6,081 | $167.7K |
| Oct 1, 2026 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 plan | 9,377 | $76.1K |
| Sep 16, 2026 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 plan | 13,398 | $113.3K |
| Sep 16, 2026 | LO FRANCIS Chief People Officer | Sale 10b5-1 plan | 7,869 | $224.8K |
| Sep 16, 2026 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 plan | 53,091 | $644.5K |
| Sep 16, 2026 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 plan | 15,629 | $62.4K |
| Sep 16, 2026 | LO FRANCIS Chief People Officer | Option exercise 10b5-1 plan | 23,442 | $190.3K |
| Sep 16, 2026 | LO FRANCIS Chief People Officer | Sale 10b5-1 plan | 107,537 | $3.01M |
| Sep 15, 2026 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Sale 10b5-1 plan | 1,195 | $32.3K |
| Aug 31, 2026 | OWEN KATEY EINTERZ Director | Gift | 12,539 | — |
| Aug 26, 2026 | OWEN KATEY EINTERZ Director | Sale | 9,615 | $250.0K |
| Aug 18, 2026 | HERSHBERG ROBERT Director | Sale | 15,664 | $382.4K |
| Aug 18, 2026 | HERSHBERG ROBERT Director | Option exercise | 15,000 | $94.8K |
| Aug 18, 2026 | HERSHBERG ROBERT Director | Sale | 15,000 | $365.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Adaptive Biotechnologies Corp
Free account. Everything above stays public.
Write why you follow Adaptive Biotechnologies Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading